Drug Profile
Geptanolimab - Apollomics
Alternative Names: Aibining; APL-501; CBT 501; GB 226; Genolimzumab - Apollomics; Geptanolimab - Genor Biopharma; Recombinant humanised anti-PD-1 monoclonal antibodyLatest Information Update: 23 Jan 2024
Price :
$50
*
At a glance
- Originator CBT Pharmaceuticals; Crown Bioscience
- Developer Apollomics; Genor Biopharma; HUTCHMED
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Small molecules
- Mechanism of Action Antibody-dependent cell cytotoxicity; Programmed cell death-1 receptor antagonists; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Peripheral T-cell lymphoma
- Phase III Cervical cancer
- Phase II Alveolar soft part sarcoma; Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
- Phase I/II Liver cancer
- Phase I Colorectal cancer; Non-small cell lung cancer
- No development reported Lymphoma; Solid tumours
Most Recent Events
- 23 Jan 2024 Phase-I development in Colorectal-cancer (Combination therapy, Late-stage disease, Metastatic disease, Recurrent, Second-line therapy or greater) is still ongoing in China (IV) (Genor Pharma pipeline, January 2024)
- 23 Jan 2024 Phase-I development in Non-small-cell-lung-cancer (Combination therapy, Metastatic disease, Second-line therapy or greater) is still ongoing in China (IV) (Genor Pharma pipeline, January 2024)
- 23 Jan 2024 Phase-III clinical trials in Cervical cancer (Metastatic disease, Recurrent, Second-line therapy or greater) in China (IV) (Genor Pharma pipeline, January 2024)